Indivior PLC announced that it was added to the S&P SmallCap 600 index on December 22, 2025, following earlier inclusions in the S&P 1000 and the S&P Pharmaceuticals Select Industry Index and ...

RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics.

Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...

Bicycle Health, a provider of telemedicine treatment for opioid use disorder, announced that it will make prescriptions for buprenorphine extended release injections (known as Sublocade) available to ...

Sublocade is intended for use as part of a complete treatment program that includes counseling and psychosocial support. Sublocade is intended for use as part of a complete treatment program that ...